CN1040758C - 二氮杂双环壬烷的结晶形式的富马酸盐的制备方法 - Google Patents

二氮杂双环壬烷的结晶形式的富马酸盐的制备方法 Download PDF

Info

Publication number
CN1040758C
CN1040758C CN92111096A CN92111096A CN1040758C CN 1040758 C CN1040758 C CN 1040758C CN 92111096 A CN92111096 A CN 92111096A CN 92111096 A CN92111096 A CN 92111096A CN 1040758 C CN1040758 C CN 1040758C
Authority
CN
China
Prior art keywords
compound
nonane
salt
diazabicyclo
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN92111096A
Other languages
English (en)
Chinese (zh)
Other versions
CN1072931A (zh
Inventor
U·雪恩
W·海特曼
U·麦茨尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Pharmaceuticals GmbH
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of CN1072931A publication Critical patent/CN1072931A/zh
Application granted granted Critical
Publication of CN1040758C publication Critical patent/CN1040758C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CN92111096A 1991-12-03 1992-09-26 二氮杂双环壬烷的结晶形式的富马酸盐的制备方法 Expired - Lifetime CN1040758C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4139763A DE4139763A1 (de) 1991-12-03 1991-12-03 Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel
DEP4139763.0 1991-12-03

Publications (2)

Publication Number Publication Date
CN1072931A CN1072931A (zh) 1993-06-09
CN1040758C true CN1040758C (zh) 1998-11-18

Family

ID=6446125

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92111096A Expired - Lifetime CN1040758C (zh) 1991-12-03 1992-09-26 二氮杂双环壬烷的结晶形式的富马酸盐的制备方法

Country Status (25)

Country Link
US (1) US5324732A (enExample)
EP (1) EP0550383B1 (enExample)
JP (1) JP3180848B2 (enExample)
KR (1) KR100252389B1 (enExample)
CN (1) CN1040758C (enExample)
AT (1) ATE124411T1 (enExample)
AU (1) AU652869B2 (enExample)
CA (1) CA2084489C (enExample)
CZ (1) CZ281930B6 (enExample)
DE (2) DE4139763A1 (enExample)
DK (1) DK0550383T3 (enExample)
DZ (1) DZ1636A1 (enExample)
ES (1) ES2073900T3 (enExample)
FI (1) FI100053B (enExample)
HK (1) HK1006568A1 (enExample)
HU (3) HU213672B (enExample)
IL (1) IL103819A (enExample)
LT (1) LTIP230A (enExample)
MX (1) MX9206988A (enExample)
NO (1) NO300687B1 (enExample)
NZ (1) NZ245227A (enExample)
PH (1) PH31114A (enExample)
SK (1) SK279519B6 (enExample)
TW (1) TW274084B (enExample)
ZA (1) ZA928863B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4421324A1 (de) * 1994-06-17 1995-12-21 Kali Chemie Pharma Gmbh Neue 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen enthaltende Arzneimittel
CA2426666A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
CN1822833A (zh) * 2003-07-21 2006-08-23 索尔瓦药物有限公司 3,7－二氮杂双环[3,3,1]壬烷化合物在治疗和/或预防男性患者心律失常中的用途
US20050054667A1 (en) * 2003-07-21 2005-03-10 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting anti-arrhythmic events in male human patients
WO2005030207A1 (en) * 2003-09-26 2005-04-07 Solvay Pharmaceuticals Gmbh Use of 3, 7-diazabicyclo (3.3.1) nonane compounds for the treatment of brugada syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2375235A1 (fr) * 1976-12-23 1978-07-21 Bayer Ag Nouveaux diazabicyclo(3,3,1)nonanes, leur procede de preparation et medicament les contenant
EP0103833A2 (de) * 1982-09-18 1984-03-28 Kali-Chemie Pharma GmbH Diazabicyclo-(3,3,1)-nonane
EP0306871A2 (de) * 1987-09-09 1989-03-15 Kali-Chemie Pharma GmbH 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2551283C3 (de) * 1975-11-14 1981-02-19 Hokuriku Pharmaceutical Co., Ltd., Katsuyama, Fukui (Japan) Monofumarsäuresalz von 3-Pyridylmethylnikotinat und Verfahren zu seiner Herstellung
US4971992A (en) * 1989-03-27 1990-11-20 Hoechst-Roussel Pharmaceuticals Inc. Carbonate derivatives of eseroline
DE4019080A1 (de) * 1990-06-15 1991-12-19 Kali Chemie Pharma Gmbh Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2375235A1 (fr) * 1976-12-23 1978-07-21 Bayer Ag Nouveaux diazabicyclo(3,3,1)nonanes, leur procede de preparation et medicament les contenant
EP0103833A2 (de) * 1982-09-18 1984-03-28 Kali-Chemie Pharma GmbH Diazabicyclo-(3,3,1)-nonane
EP0306871A2 (de) * 1987-09-09 1989-03-15 Kali-Chemie Pharma GmbH 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
FI925482L (fi) 1993-06-04
MX9206988A (es) 1993-06-01
SK332292A3 (en) 1998-12-02
NO924647L (no) 1993-06-04
EP0550383A1 (de) 1993-07-07
CA2084489A1 (en) 1993-06-04
KR930012772A (ko) 1993-07-21
NZ245227A (en) 1994-06-27
JPH05247040A (ja) 1993-09-24
FI925482A0 (fi) 1992-12-02
SK279519B6 (sk) 1998-12-02
US5324732A (en) 1994-06-28
CZ281930B6 (cs) 1997-04-16
HU9203698D0 (en) 1993-03-29
DZ1636A1 (fr) 2002-02-17
HUT63417A (en) 1993-08-30
TW274084B (enExample) 1996-04-11
IL103819A0 (en) 1993-04-04
CN1072931A (zh) 1993-06-09
KR100252389B1 (ko) 2000-05-01
AU2981592A (en) 1993-06-10
ATE124411T1 (de) 1995-07-15
DE59202726D1 (de) 1995-08-03
JP3180848B2 (ja) 2001-06-25
ES2073900T3 (es) 1995-08-16
CA2084489C (en) 2002-10-08
EP0550383B1 (de) 1995-06-28
HU213672B (en) 1997-09-29
DK0550383T3 (da) 1995-08-28
CZ332292A3 (en) 1993-08-11
PH31114A (en) 1998-02-23
IL103819A (en) 1996-09-12
LTIP230A (en) 1994-05-15
FI100053B (fi) 1997-09-15
DE4139763A1 (de) 1993-06-09
ZA928863B (en) 1993-05-13
HU210215A9 (en) 1995-02-28
HK1006568A1 (en) 1999-03-05
NO924647D0 (no) 1992-12-02
NO300687B1 (no) 1997-07-07
AU652869B2 (en) 1994-09-08

Similar Documents

Publication Publication Date Title
US11613529B2 (en) Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide
US20090209757A1 (en) Processes for the preparation and purification of paliperidone palmitate
WO2014036814A1 (zh) 双氟代磺酰亚胺锂的制备方法
WO2013074817A1 (en) Solid state forms of linagliptin
KR20050058492A (ko) 클로피도그렐 황산수소염의 결정질 형태 1의 제조 방법
Yang et al. Crystal structure, thermodynamics, and crystallization of bio-based polyamide 56 salt
CN1072931A (zh) 9，9-亚烷基-3，7-二氮杂双环壬烷化合物的结晶富马酸盐以及含该化合物的药剂
AU2020224678B2 (en) Solid polymorphs of a FLNA-binding compound and its hydrochloride salts
SU660592A3 (ru) Способ получени -циклоалкилметил-2-фениламино-имидазолинов-(2) или их солей
JPH0256358B2 (enExample)
CN1150193C (zh) B晶型8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂二环(4.3.0)壬烷-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸
EP1791839A1 (en) PREPARATION OF 9-HYDROXY-3- (2-HYDROXYETHYL) -2-METHYL-4H-PYRID0[1, 2-a]PYRIMIDIN-4-ONE AND CRYSTALS THEREOF
HK1006568B (en) Medicament containing crystalline fumaric acid salts of 9,9-alkylen-3,7 diazabicyclononane compounds
CN1135230C (zh) A晶型8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂二环[4.3.0]壬烷-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸
CN117677615A (zh) 一种螺环化合物的盐型、晶型及其制备方法
CA3103153A1 (en) Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof
AU2012213666A1 (en) Method of preparation of metaxalone
US2438883A (en) Process of making ribonolactone
CN116283958B (zh) 唑吡坦共晶体及其制备方法
JP2024544717A (ja) 芳香環誘導体の結晶及びその調製方法と使用
CN114957320A (zh) 一种有机膦酸羧酸钠显影促进剂及其制备方法
JPS62215563A (ja) 不飽和ジカルボン酸イミド系化合物の製法
EA041474B1 (ru) Способы получения ag-10, его промежуточных соединений и их солей
HK1178159A1 (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C56 Change in the name or address of the patentee

Owner name: ABBOTT PRODUCTS, INC.

Free format text: FORMER NAME: SOLVAY PHARMACEUTICALS GMBH

CP01 Change in the name or title of a patent holder

Address after: Hannover, Federal Republic of Germany

Patentee after: Solvay Pharm GmbH

Address before: Hannover, Federal Republic of Germany

Patentee before: Solvay Pharmaceuticals GmbH

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20120926

Granted publication date: 19981118